![]() As shown in Exhibit 2, the continuation of this trend will surely see APAC surpass RoW as soon as next year. ![]() These RoW trials are defined as studies that do not contain a clinical site in an APAC country, although it is worth noting that a portion of APAC trials will also have sites in other regions. In contrast, the total number of trial starts in the rest of the world decreased at a CAGR of -0.4% from 8,080 trials in 2012 to 7,801 trials in 2021. ![]() In particular, almost every year since 2016 has seen double digit increases in the number of new clinical trial initiations, as shown in Exhibit 1. Much of this growth is back-ended towards recent years. The total number of Phase I–IV trial starts in APAC increased from 4,562 trials in 2012 to 7,718 trials in 2021, with a compound annual growth rate (CAGR) of 5.4%. The Rise Of APACĬlinical trial activity in APAC has increased considerably over the past decade. Of course, this is often not the case, with longstanding biases towards studies in the US and Europe, where health care infrastructure and the pharmaceutical market are generally more mature. ![]() It is often said that “disease knows no borders,” but is the same true for clinical development? Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |